12:00 AM
Apr 08, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Oprozomib: Preliminary Phase Ib/II data

Onyx reported preliminary data from an open-label, dose-escalation, U.S. Phase Ib/II trial in 32 patients with hematologic malignancies showing that a once-daily modified-release (MR) formulation of oral oprozomib had a trend towards lower grades of gastrointestinal adverse events compared to a once-daily split-dose powder-in-capsule (PIC) formulation of oral oprozomib. In 23 patients evaluable for a response, oprozomib led to an ORR...

Read the full 285 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >